Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 24;61(11):e01402-17.
doi: 10.1128/AAC.01402-17. Print 2017 Nov.

Relationships of Vancomycin Pharmacokinetics to Body Size and Composition Using a Novel Pharmacomorphomic Approach Based on Medical Imaging

Affiliations

Relationships of Vancomycin Pharmacokinetics to Body Size and Composition Using a Novel Pharmacomorphomic Approach Based on Medical Imaging

Manjunath P Pai et al. Antimicrob Agents Chemother. .

Abstract

Antibiotics such as vancomycin are empirically dosed on the basis of body weight, which may not be optimal across the expanding adult body size distribution. Our aim was to compare the relationships between morphomic parameters generated from computed tomography images to conventional body size metrics as predictors of vancomycin pharmacokinetics (PK). This single-center retrospective study included 300 patients with 1,622 vancomycin concentration (52% trough) measurements. Bayesian estimation was used to compute individual vancomycin volume of distribution of the central compartment (Vc) and clearance (CL). Approximately 45% of patients were obese with an overall median (5th, 95th percentile) weight and body mass index of 87.2 (54.7, 123) kg and 28.8 (18.9, 43.7) kg/m2, respectively. Morphomic parameters of body size such as body depth, total body area, and torso volume of the twelfth thoracic through fourth lumbar vertebrae (T12 to L4) correlated with Vc. The relationship of vancomycin Vc was poorly predicted by body size but was stronger with T12-to-L4 torso volume (coefficient of determination [R2] = 0.11) than weight (R2 = 0.04). No relationships between vancomycin CL and traditional body size metrics could be discerned; however, relationships with skeletal muscle volume and total psoas area were found. Vancomycin CL independently correlated with total psoas area and inversely correlated with age. Thus, vancomycin CL was significantly related to total psoas area over age (R2 = 0.23, P < 0.0001). This proof-of-concept study suggests a potential role for translation of radiographic information into parameters predictive of drug pharmacokinetics. Prediction of individual antimicrobial pharmacokinetic parameters using analytic morphomics has the potential to improve antimicrobial dose selection and outcomes of obese patients.

Keywords: antimicrobial safety; drug dosing; morphomics; muscle; precision medicine; psoas; safety.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Representative images of key morphomic parameters that include (A) body depth (red arrow), fascia area (yellow border), total body area (purple border), and subcutaneous fat area (area between purple and yellow borders); (B) total psoas area (sum of left and right areas within purple border); (C) spinous process to back skin (yellow line), vertebral body to fascia (red line), and fascia to front skin (turquoise line); (D) skeletal muscle area (shaded region represents muscle tissue within the fascial boundary).
FIG 2
FIG 2
Violin plot of the distribution of concentrations obtained from subjects to inform the pharmacokinetic parameter estimates based on measurement type (percentage of total samples).
FIG 3
FIG 3
Scatter and linear regression fits of vancomycin volume of distribution (vertical axis) over weight.

Similar articles

Cited by

References

    1. Pai MP. 2012. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy 32:856–868. doi:10.1002/j.1875-9114.2012.01108.x. - DOI - PubMed
    1. Wells JC, Fewtrell MS. 2006. Measuring body composition. Arch Dis Child 91:612–617. doi:10.1136/adc.2005.085522. - DOI - PMC - PubMed
    1. Hanley MJ, Abernethy DR, Greenblatt DJ. 2010. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49:71–87. doi:10.2165/11318100-000000000-00000. - DOI - PubMed
    1. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index) 2011. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377:557–567. doi:10.1016/S0140-6736(10)62037-5. - DOI - PMC - PubMed
    1. Green B, Duffull SB. 2004. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58:119–133. doi:10.1111/j.1365-2125.2004.02157.x. - DOI - PMC - PubMed

Publication types